ReviewEXCLI journal2014
Non-alcoholic fatty liver disease, diet and gut microbiota.
Review in EXCLI journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Association Between Dietary Acid Load and Non-Alcoholic Fatty Liver Disease.Food science & nutrition · 2026Review
- Dietary Acid Load (DAL), Glycated Hemoglobin A1c (HbA1c), and Metabolic Syndrome (MeS) Mediate the Association of the Adherence to the Dietary Approaches to Stopping Hypertension (DASH) and Mediterranean Diet (MeD) With Nonalcoholic Fatty Liver Disease.Frontiers in nutrition · 2022Article
- Diet-Regulating Microbiota and Host Immune System in Liver Disease.International journal of molecular sciences · 2021Review
- Gut microbiota, fatty liver disease, and hepatocellular carcinoma.Liver research (Beijing, China) · 2018Article
- Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.Nutrients · 2017Review
- A Critical Review on Health Promoting Benefits of Edible Mushrooms through Gut Microbiota.International journal of molecular sciences · 2017Review
- Schisandrin B: A Double-Edged Sword in Nonalcoholic Fatty Liver Disease.Oxidative medicine and cellular longevity · 2016Review
- In vitro Modulation of the LPS-Induced Proinflammatory Profile of Hepatocytes and Macrophages- Approaches for Intervention in Obesity?Frontiers in cell and developmental biology · 2016Article
- The improvement of large High-Density Lipoprotein (HDL) particle levels, and presumably HDL metabolism, depend on effects of low-carbohydrate diet and weight loss.EXCLI journal · 2016Article
- The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.Hepatology international · 2015Review
Corrections and comments
- Retraction · 2017-10-18Euphemisms for Plagiarism · Plagiarism of/in Article ·
- Retracted
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a severe liver disease that is increasing in prevalence with the worldwide epidemic of obesity and its related insulin-resistance state. Evidence for the role of the gut microbiota in energy storage and the subsequent development of obesity and some of its related diseases is now well established. More recently, a new role of gut microbiota has emerged in NAFLD. The gut microbiota is involved in gut permeability, low-grade inflammation and immune balance, it modulates dietary choline metabolism, regulates bile acid metabolism and produces endogenous ethanol. All of these factors are molecular mechanisms by which the microbiota can induce NAFLD or its progression toward overt non-alcoholic steatohepatitis. Modification of the gut microbiota composition and/or its biochemical capacity by specific dietary or pharmacological interventions may advantageously affect host metabolism. Large-scale intervention trials, investigating the potential benefit of prebiotics and probiotics in improving cardiometabolic health in high-risk populations, are fervently awaited.
Indexed as
Identifiers
26417275PMC4464355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.